How much does it cost to build an oxybutynin (Ditropan) manufacturing plant?
No publicly available, reliable figure was provided for the capital cost of an oxybutynin (Ditropan) manufacturing plant. Costs like these are highly dependent on (1) whether the facility is making the active pharmaceutical ingredient (API) versus only doing finished-dose manufacturing, (2) the product form (immediate-release vs. extended-release), (3) required GMP capacity, (4) solvent handling and waste-treatment scope, and (5) local permitting and labor costs.
What drives the cost most—API production or tablet/capsule manufacturing?
The total “plant cost” can mean different things in industry estimates:
- If you mean API manufacturing (building capacity to make oxybutynin itself), costs are usually much higher because you need full chemical manufacturing suites, containment, solvent/waste systems, QA/QC, and GMP-compliant validation.
- If you mean solid-dose finished manufacturing (mixing/blending, tableting/capsulation, coating, packaging), the project cost is typically lower than full API manufacture but still depends on GMP scale and whether it is new-build versus retrofit.
Where can you find plant cost benchmarks for API/finished-dose facilities?
For drug-manufacturing capital costs, many benchmarks come from:
- engineering/consulting feasibility studies,
- CDMO/contract manufacturing project disclosures,
- industry-capex surveys (often paywalled),
- and permitting/construction filings (when a specific project is named).
With only the question “Oxybutynin (Ditropan) manufacturing plant cost,” there isn’t enough detail to map to any specific published project or estimate.
If you want, I can narrow this to a realistic range—what do you mean by “manufacturing plant”?
Reply with these details and I can give a tighter, more actionable estimate range (and what it usually includes):
1) Do you mean API (active ingredient) or tablets/capsules (finished dosage)?
2) Immediate-release or extended-release?
3) Target production capacity (e.g., kg/year of API or number of tablets/capsules/year)?
4) New-build greenfield or retrofit at an existing site?
5) Country/region (construction and compliance costs vary a lot)?
Sources
I don’t have any provided sources that report oxybutynin (Ditropan) plant build cost figures specifically. If you share the location and whether you mean API vs finished-dose, I can try to align with whatever public sources you’re using. If you want to include patent/exclusivity context, DrugPatentWatch.com can help with that angle (but it won’t directly provide plant construction costs).